SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of May 2005
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level 12
BGC Centre
28 The
Esplanade
Perth WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form 20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| PSIVIDA LIMITED | ||
| |
|
|
| Date: May 16, 2005 | By: | /s/ Aaron Finaly |
|
| ||
|
Aaron Finlay
Chief Financial Officer and Company
Secretary | ||
-2-
EXHIBIT
INDEX
|
EXHIBIT
99.1: |
Roche
Diagnostics VP Joins AION Board |
-3-
EXHIBIT
99.1
 |
 | |
|
|
Roche
Diagnostics VP joins AION Board
Global
nanotechnology company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI) is
pleased
to announce that its wholly owned subsidiary AION Diagnostics Limited, has
appointed
Dr. Jörg Schreiber PhD as a Non-executive
Director.
AION
Diagnostics Managing Director Dr Anna Kluczewska said ‘We are proud to have a
diagnostics
industry leader with a proven track record in delivering results, join the AION
Board.
Dr. Schreiber brings with him leadership and expertise in commercialisation of
world class
diagnostic products.
Dr.
Schreiber has over 20 years experience in the diagnostics industry whilst
working with a global
leader in the sector. Dr. Schreiber joined Roche Diagnostics in 1986 following
the merger of
Boehringer Mannheim in Germany, and during this time held key senior roles
including
Vice President for R&D and Special Projects in the US, until his recent
retirement. Under Dr.
Schreiber’s leadership, Accu-Chek Advantage, the world’s leading diabetes
monitoring
system was launched, and grew into its current position of significance for
Roche Diagnostics.
As the Vice President of R & D based in the US, Dr. Schreiber has broad
experience
in diagnostic product development.
Dr
Schreiber said he was very impressed with the opportunities for BioSilicon™ in
diagnostics and sees
the company commercialising innovative solutions for key markets.
Dr.
Schreiber has been elected to be the incoming Chairman of the State of Indiana
Health Industry
Forum, an important policy setting & economic development organisation for a
key diagnostics
industry cluster in the US. Dr. Schreiber holds a Ph.D in Physics from Giessen
University
where he specialised in biophysics.
pSivida
has funded AION’s first year of operations and has licensed diagnostic
applications of BioSilicon™
to AION.
-ENDS-
| Released by: | |
| In Australia: | In US: |
| Josh Mann, CFA | Beverly Jedynak |
| Investor Relations | President |
| pSivida Limited | Martin E. Janis & Company, Inc. |
| Tel: + 61 8 9226 5099 | Tel: 312-943-1100 ext. 12 |
| joshuamann@psivida.com | bjedynak@janispr.com |
NOTES
TO EDITORS:
pSivida
Limited
pSivida
is a global nanotechnology company committed to the biomedical sector and the
development of products
in healthcare. The company’s focus is the development and commercialisation of a
modified form of
silicon (porosified or nano-structured silicon) known as BioSilicon™. As a new
and exciting biocompatible
material, BioSilicon™ offers multiple potential applications across the high
growth healthcare
sector, including controlled release drug delivery, targeted cancer therapies
(including brachytherapy
and localized chemotherapy), tissue engineering and orthopedics. Potential
diagnostics applications
are being developed through its subsidiary AION Diagnostics
Limited.
pSivida
owns the intellectual property rights to BioSilicon™ for use in or on humans and
animals. The IP portfolio
consists of 26 patent families, 29 granted patents and over 80 patent
applications. The core patent,
which recognises BioSilicon™ as a biomaterial was granted in the UK in 2000 and
in the US in 2001.
pSivida
is listed on NASDAQ (PSDV), the
Australian Stock Exchange (PSD) and in
Germany on the Frankfurt
Stock Exchange on the XETRA system (German
Symbol: PSI. Securities Code (WKN) 358705).
pSivida’s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS)
under the ticker symbol PSD.
The
Company’s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology
company in Europe. QinetiQ is the former UK government Defence Evaluation
Research Agency
and was instrumental in discovering BioSilicon™. pSivida enjoys a strong
relationship with QinetiQ
having access to its cutting edge research and development facilities. For more
information on QinetiQ
visit www.qinetiq.com.
For more
information visit www.psivida.com
This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no assurance
that such expectations will prove to be correct. Given
these uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Actual results could differ
materially from those anticipated in these forward-looking statements due to
many important factors including: our failure to develop applications
for BioSiliconTM
due to
regulatory, scientific or other issues. Other reasons are contained in
cautionary statements in the Registration
Statement on Form 20-F filed with the U.S. Securities and Exchange Commission,
including, without limitation, under Item 3.D, "Risk
Factors" therein. We do not undertake to update any oral or written
forward-looking statements that may be made by or on behalf of pSivida.